Global Bio-chem Technology's (HKG:0809) attributable profit fell to HK$769.6 million in 2024 from HK$4.22 billion in 2023, according to an annual report filed Wednesday with the Hong Kong bourse.
Earnings per share at the biotechnology firm increased to HK$0.029 from HK$0.291 in the previous year.
Revenue grew to HK$2 billion from HK$1.37 billion a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。